Arcutis Biotherapeutics Inc (NASDAQ: ARQT) kicked off on Tuesday, up 3.15% from the previous trading day, before settling in for the closing price of $12.68. Over the past 52 weeks, ARQT has traded in a range of $3.11-$16.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 379.27%. While this was happening, its average annual earnings per share was recorded 64.85%. With a float of $102.98 million, this company’s outstanding shares have now reached $117.00 million.
Let’s determine the extent of company efficiency that accounts for 296 employees. In terms of profitability, gross margin is 89.43%, operating margin of -131.16%, and the pretax margin is -140.72%.
Arcutis Biotherapeutics Inc (ARQT) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 12.02%, while institutional ownership is 103.01%. The most recent insider transaction that took place on Jan 02 ’25, was worth 146,714. In this transaction Director of this company sold 10,000 shares at a rate of $14.67, taking the stock ownership to the 151,944 shares. Before that another transaction happened on Jan 02 ’25, when Company’s Director proposed sale 10,000 for $14.67, making the entire transaction worth $146,714.
Arcutis Biotherapeutics Inc (ARQT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 64.85% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Take a look at Arcutis Biotherapeutics Inc’s (ARQT) current performance indicators. Last quarter, stock had a quick ratio of 2.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.87 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Looking closely at Arcutis Biotherapeutics Inc (NASDAQ: ARQT), its last 5-days average volume was 1.72 million, which is a drop from its year-to-date volume of 1.94 million. As of the previous 9 days, the stock’s Stochastic %D was 5.66%. Additionally, its Average True Range was 1.03.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 61.81%, which indicates a significant increase from 13.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.45% in the past 14 days, which was higher than the 63.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.63, while its 200-day Moving Average is $10.21. However, in the short run, Arcutis Biotherapeutics Inc’s stock first resistance to watch stands at $13.37. Second resistance stands at $13.67. The third major resistance level sits at $13.96. If the price goes on to break the first support level at $12.78, it is likely to go to the next support level at $12.49. Now, if the price goes above the second support level, the third support stands at $12.19.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
The company with the Market Capitalisation of 1.53 billion has total of 117,045K Shares Outstanding. Its annual sales at the moment are 59,610 K in contrast with the sum of -262,140 K annual income. Company’s last quarter sales were recorded 44,760 K and last quarter income was -41,540 K.
